The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States

Published:2020-07-14 Issue:8 Volume:95 Page:960-965
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Malec Lynn M.¹²^ORCID,Cheng Dunlei³,Witmer Char M.⁴,Jaffray Julie⁵^ORCID,Kouides Peter A.⁶,Haley Kristina M.⁷^ORCID,Sidonio Robert F.⁸,Johnson Kelsey¹,Recht Michael³⁷^ORCID,White Gilbert¹²,Croteau Stacy E.⁹^ORCID,Ragni Margaret V.¹⁰¹¹

Affiliation:

1. Versiti Blood Research Institute Milwaukee Wisconsin

2. Medical College of Wisconsin Milwaukee Wisconsin

3. American Thrombosis and Hemostasis Network Chicago Illinois

4. The Children's Hospital of Philadelphia Philadelphia Pennsylvania

5. Keck School of MedicineChildren's Hospital Los Angeles, University of Southern California Los Angeles California

6. Mary M. Gooley Hemophilia Center Rochester New York

7. Oregon Health & Science University Portland Oregon

8. Children's Healthcare of Atlanta Atlanta Georgia

9. Boston Hemophilia CenterBoston Children's Hospital Boston Maryland

10. Hemophilia Center of Western Pennsylvania Pittsburgh Pennsylvania

11. University of Pittsburgh Pittsburgh Pennsylvania

Funder

Hemophilia of Georgia

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25844

Reference12 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

3. A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

4. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life

5. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In vivo genome editing using 244-cis LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice;Molecular Therapy - Nucleic Acids;2023-12

2. Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data;Journal of Medical Economics;2023-10-25

3. Serious Blood Disorders: A Focus on Sickle Cell Disease and Hemophilia;Palliative Care in Hematologic Malignancies and Serious Blood Disorders;2023

4. rFVIII‐Fc in severe haemophilia A: The incentive switch in case of high risk of joint bleedings;European Journal of Clinical Investigation;2022-06-27

5. Resource utilization and treatment costs of patients with severe hemophilia A: Real‐world data from the ATHNdataset;eJHaem;2022-03-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3